Therapeutic response and safety of radioligand therapy with ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients.

IF 2.8 4区医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2024-08-13 DOI:10.1007/s12032-024-02466-7

Wardah Ashfaq, Khurram Rehman, Abubaker Shahid, Muhammad Numair Younis

{"title":"Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients.","authors":"Wardah Ashfaq, Khurram Rehman, Abubaker Shahid, Muhammad Numair Younis","doi":"10.1007/s12032-024-02466-7","DOIUrl":null,"url":null,"abstract":"Prostate cancer is one of the most common cancers and leading cause of death due to cancer across the globe. This persuaded researchers to devise innovative treatment modalities that may prove effective, safe, and demonstrate better outcomes in terms of patient morbidity and survival. The advancement in theranostics such as lutetium-177 (177Lu)-PSMA-617 radioligand therapies can target prostate cancer cells causing negligible or no damage to most of the normal tissues in patients. It has been proven to effectively improve the quality of life and progression-free survival. In this study, stage IV metastatic castration-resistant prostate cancer patients were treated with 177Lu-PSMA-617, and the therapeutic response and safety of 177Lu-PSMA-617 radioligand therapy were evaluated six months after the treatment. Additionally, molecular docking studies were also conducted to find the possible mechanism at the molecular level that causes the effectiveness of 177Lu-PSMA-617 in prostate cancer.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"41 9","pages":"226"},"PeriodicalIF":2.8000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02466-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer is one of the most common cancers and leading cause of death due to cancer across the globe. This persuaded researchers to devise innovative treatment modalities that may prove effective, safe, and demonstrate better outcomes in terms of patient morbidity and survival. The advancement in theranostics such as lutetium-177 (¹⁷⁷Lu)-PSMA-617 radioligand therapies can target prostate cancer cells causing negligible or no damage to most of the normal tissues in patients. It has been proven to effectively improve the quality of life and progression-free survival. In this study, stage IV metastatic castration-resistant prostate cancer patients were treated with ¹⁷⁷Lu-PSMA-617, and the therapeutic response and safety of ¹⁷⁷Lu-PSMA-617 radioligand therapy were evaluated six months after the treatment. Additionally, molecular docking studies were also conducted to find the possible mechanism at the molecular level that causes the effectiveness of ¹⁷⁷Lu-PSMA-617 in prostate cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用 177Lu-PSMA-617 对转移性阉割耐药前列腺癌患者进行放射性配体治疗的治疗反应和安全性。

前列腺癌是全球最常见的癌症之一，也是癌症致死的主要原因。这促使研究人员设计创新的治疗模式，以证明其有效、安全，并在患者发病率和生存率方面取得更好的结果。镥-177（177Lu）-PSMA-617 放射性配体疗法等治疗学的进步可以靶向前列腺癌细胞，对患者的大部分正常组织造成的损害微乎其微，甚至没有损害。事实证明，它能有效改善患者的生活质量和无进展生存期。在这项研究中，IV期转移性阉割耐药前列腺癌患者接受了177Lu-PSMA-617治疗，并在治疗6个月后评估了177Lu-PSMA-617放射性配体疗法的治疗反应和安全性。此外，还进行了分子对接研究，以寻找导致 177Lu-PSMA-617 对前列腺癌有效的分子水平的可能机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.